Chipotle Reports In-Line and 4 Stock Analyses to Follow

Expedia Inc. (NASDAQ:EXPE): Current Price: $65.76

Benchmark Co. decided to increase its price target on the stock due to the company’s strong Q4 results and it has reiterated its Buy rating. The firm is convinced that investors should be willing to accept near-term margin compression from higher spending for an anticipated rise in the company’s global market penetration and it reiterates its Buy rating on the stock.

Your 1 Feature Stock Pick for February is hot off the press. Click here to discover it now!

Capture

The McGraw-Hill Companies, Inc. (NYSE:MHP): Current Price: $45.74

Benchmark Co. is convinced that McGraw-Hill keeps its favorable fundamental growth prospects after the Department of Justice lawsuit against its S&P unit. The firm decided to decrease its price target to $57 from $64 on the shares, but it reiterates its Buy rating on the stock as it believes that the recent pullback in shares is overdone.

Capture

Your 1 Feature Stock Pick for February is hot off the press. Click here to discover it now!

Conceptus, Inc. (NASDAQ:CPTS): Current Price: $22.12

Conceptus reported stronger Q4 results than predicted, influencing Cantor to believe that the company will keep generating double digit growth during 2013 and 2014. The firm keeps a Buy rating and has raised its price target to $25 from $22 on the stock.

Capture

Shutterfly, Inc. (NASDAQ:SFLY): Current Price: $39.65

Cantor decided to raise its price target on Shutterfly following the company’s reports of much stronger Q4 results than predicted. The firm predicts that increased estimates and the large short position in the stock will cause shares to rise during the short-term. Cantor keeps its Buy rating on the stock.

Capture

Chipotle Mexican Grill, Inc. (NYSE:CMG): Current Price: $304.92

Chipotle reported in-line Q4 results and provided in-line FY13 guidance, causing Bernstein to predict that the company’s marketing initiatives and possible price hikes will boost its comps during the year compared to Q4. The firm is convinced that the stock’s multiple has the ability to expand and it keeps its Outperform rating on the stock.

Capture

Don’t Miss: Is Hologic a Worthwhile Investment?